Title:

MLL1 modulates IgM and inflammatory cytokines in Waldenström macroglobulinemia

Poster

Preview Converted Images may contain errors

Abstract

Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma associated with the accumulation of lymphoplasmacytic cells in the bone marrow (BM) and a high level of monoclonal IgM protein in the serum. Genome-wide studies revealed genomic alternations in WM, with the most prevalent being a point mutation in the myeloid differentiation primary response gene 88 (MyD88) resulting in an amino acid change (L265P) that is present in over 90% of WM patients. MyD88 is an effector of Toll-like receptor (TLR) signaling pathway that mediates inflammatory cytokine expression and secretion upon activation. We have identified a change in the chromatin landscape in response to TLR stimulation in WM cells. We found increased levels of trimethylation of histone 3 lysine 4 (H3K4me3) at the promoters of the inflammatory cytokines IL-6 and CCL2 by chromatin immunoprecipitation (ChIP) assay followed by qPCR. This modification is catalyzed by six related homologs of the yeast histone methyltransferase (HMT) family. In addition, we have identified the Mixed-lineage leukemia 1 (MLL1) as the enzyme bound to these promoters in response to TLR-MyD88 stimulation. Analysis of WM cell lines and primary WM patient cells showed that MLL1 and its binding partner, menin, are expressed at significantly higher levels in CD19+CD138+ cells from WM patients compared to CD19+ cells from peripheral blood . We found an increase in H3K4me3 deposition on IL-6 and CCL2 promoters during early (1-3 hr) and late (12-24 hr) kinetics following TLR-MyD88 stimulation with LPS. This also coincided with increased deposition of MLL1 on these cytokine promoters by ChIP-qPCR. Disruption of menin-MLL1 using the MI-2 or MI-503 menin-MLL1 inhibitors significantly reduced IL-6 and CCL2 expression in WM cell lines. Finally, MLL1 knockdown using RNAi significantly reduces IgM expression in BCWM.1, MWCL and RPCI-WM1 and secretion and treatment of WM cell lines with the menin-MLL1 inhibitor significantly reduced IgM expression and secretion. Taken together, these results identify a novel role for menin-MLL1 in regulating inflammatory cytokines and IgM secretion in WM and provide the rationale for targeting these molecules in WM patients.

Authors

First Name Last Name
Sherine F Elsawa
Martin Fernandez-Zapico
Stephen M Ansell
Luciana Almada
Weiguo Han
Mona Karbalivand

File Count: 1


Leave a comment

Comments are viewable only by submitter



Submission Details

Conference GRC
Event Graduate Research Conference
Department Molecular, Cellular, and Biomedical Sciences (GRC)
Group Poster Presentation
Added April 15, 2020, 7:43 p.m.
Updated April 15, 2020, 7:44 p.m.
See More Department Presentations Here